Neutralization of Human Cytomegalovirus by Human CD13-Specific Antibodies

Terrence D. Giugni, Cecilia Söderberg,* Debby J. Ham, Robert M. Bautista, Kjell-Olof Hedlund, Erna Möller, and John A. Zaia

The mechanisms of inhibition of cytomegalovirus (CMV) infection by human CD13 (aminopeptidase N)-specific antibodies were studied. These antibodies protect CD13-negative and -positive cells from CMV infection only if incubated with the virus inoculum, suggesting they bind to CMV virions. The association of a CD13-like molecule with virions was further supported by the transfer of CD13 immunoreactivity to the surface of CD13-negative cells upon binding of CMV; the binding of CD13-specific antibodies directly to the surface of CMV virions; and the presence of anti-CD13 immunoreactive bands, including one with mobility similar to that of native cellular CD13 on immunoblots of proteins of purified CMV particles. Importantly, CD13-specific antibodies neutralize CMV in urine of neonates with congenital CMV, indicating that the CD13-like molecule is associated with normal CMV and not acquired in vitro. These studies demonstrate that a CD13-like molecule is associated with CMV particles and may be important in CMV pathogenesis.

Human cytomegalovirus (CMV), a herpesvirus, is a significant pathogen in immunocompromised hosts [1–3] that is being seen with increasing frequency in such persons. Despite the availability of antiviral agents, such as ganciclovir and foscarnet, the toxicity of these agents and the development of virus resistance suggests that strategies are needed for prevention and better management of this infection.

CMV has a large double-stranded DNA genome of ~230 kb pairs that provides a potential coding capacity of >200 proteins [4], but little is known about the role of >75% of these genes. Sequences with homology to cellular DNA have been reported within the CMV genome [5–9]. Knowledge of the potential role of these sequences in the pathogenesis of CMV infection could lead to better treatment. A number of host cell–derived molecules are associated with CMV particles [10–14], including molecules associated with the envelope [10–12] and internally within the virion [13, 14]. Immunologic cross-reactivity between a CMV-encoded protein [9] and a cellular protein and between a CMV virion–associated protein and a host cell membrane protein [10] suggests that CMV-associated molecules with immunologic cross-reactivity with host cell proteins could be important in anti-CMV immunologic reactions and in the pathogenesis of CMV-associated disease [15–18]. This idea is supported by a report in which CD13-specific antibodies were found in CMV-infected bone marrow transplant recipients [17] and in a study in which the antibodies correlated with the development of chronic graft-versus-host disease [18].

We have shown that the expression of human CD13, aminopeptidase (AP) N, on the surface of mouse fibroblasts increases binding and entry of CMV into these cells and that CD13-specific antibodies and inhibitors of AP activity inhibit CMV infection of human fibroblasts [19]. Our initial report did not address whether CD13-specific antibodies inhibited CMV infection by interacting with the host cell or with CMV virions. In the present study, we further characterized the mechanism of inhibition of CMV infection by CD13-specific antibodies and describe some of the complexities involved in these interactions.

Materials and Methods

Cells and viruses. Human embryonic lung fibroblasts (HL734 and MRC-5) and mouse NIH-3T3 cells were maintained as described [19] in bicarbonate-free MEM with Hanks' salts (GIBCO BRL, Grand Island, NY) supplemented with 25 mM HEPES, 10% fetal bovine serum, glutamine (2 mM), penicillin (50 U/mL), and streptomycin (50 μg/mL) (all from GIBCO). HAPN-3T3 and hAPN-MUT-3T3 cells were maintained as above in complete medium with the addition of 800 μg/mL G418 (Geneticin; Gibco). These cells are NIH-3T3 transfectants that express intact human CD13, hAPN-3T3 [20], or a deletion mutant of human CD13 lacking 39 amino acids (aa) from the active site hAPN-MUT-3T3 [21]. The...
Table 1. Summary of antibodies used in study of CD13-like molecule associated with CMV virions.

| Designation     | Specificity                  | Source                        | Subclass |
|-----------------|------------------------------|-------------------------------|----------|
| Ascites, U81    | Human CD13                   | D. Bourell [24]               | IgG2a    |
| Hybridoma supernatants |                  |                                |          |
| 7-5             | CMV glycoprotein B           | W. Britt [25]                 | IgG1     |
| WM47            | Human CD13                   | Dako (Carpinteria, CA) [26, 27]| IgG1     |
| 8A3.1           | Human CD13                   | T. Piela-Smith [28]           | IgG1     |
| 7B.1            | Human CD13                   | T. Piela-Smith                 | IgG1     |
| RBS             | Human CD13                   | K. Holmes [29]                | ND       |
| Purified immunoglobulins |                             |                                |          |
| 3D8             | Human CD13                   | Cultag Laboratories (South San Francisco) [26] | IgG2a    |
| L138 (anti-Leu M7) | Human CD13                   | Becton Dickinson (San Jose, CA) [26] | IgG1     |
| MY7             | Human CD13                   | Coulter Immunology (Haleah, FL) [27, 30] | IgG1     |
| SJ1D1           | Human CD13                   | ImmunoTech (Westbrook, ME) [26] | IgG1     |
| 22A5            | Human CD13                   | Leino Technologies (Ballwin, MO) [30] | ND       |
| WM15            | Human CD13                   | Pharmingen (San Diego) [26, 27] | IgG1     |
| IB10            | Human fibroblast surface     | Sigma (St. Louis) [31]        | IgM      |
| M6P-9           | Human CD14                   | Becton Dickinson [32]         | IgG2b    |
| FMC 8           | Human CD9                    | SeraLab (Crawley Down, UK)    | IgG2a    |
| IVIG            | Pooled human immunoglobulins |                                |          |
| MOPC21          | Isotype control              | Sigma                         | IgG1     |
| UPC10           | Isotype control              | Sigma                         | IgG2a    |

NOTE. ND, not done.

human glioblastoma-derived cell line (U373MG [ATCC HTB 17]; American Type Culture Collection, Rockville, MD) was maintained in bicarbonate-free MEM as described above. The Hyb7.2 cells (obtained from L. K. Vogel, Panum Institute, University of Copenhagen) are MDCK transfectants that secrete a mutant form of human CD13 corresponding to aa 65–967. This form of CD13 lacks the transmembrane domain and exists in soluble form [22]. The Hyb7.2 cells were maintained as described for the hAPN-3T3 cells.

CMV strains AD169 and RC256, a recombinant Towne strain with the Escherichia coli β-galactosidase (β-gal) gene under the control of the CMV major early gene promoter [23], were propagated in human embryonic lung fibroblasts grown in complete medium, and titers were determined as described [19]. Urine specimens from neonates with congenital CMV infection known to be viremic (provided by J. Rabalais, Kosair Children’s Hospital, Louisville) were stored by 1:1 dilution in 50% sucrose, 12 mM K2HPO4, 7.5 mM KH2PO4 at −70°C until use. The virus titer in urine samples was determined by expression of the major immediate early (mIE) protein (UL123) as described for the CMV laboratory strains [19].

Immunologic reagents. We used a panel of 11 different human CD13-specific mouse monoclonal antibodies (MAbs) and various control antibodies in the form of ascites, hybridoma supernatants, or purified mouse immunoglobulin. The source and isotype, if known, of each antibody used is listed in table 1. The characterization of the interactions of the CD13-specific MAbs with human CD13 has been described [19, 24, 26–30]. It has been suggested that MAbs directed toward CD13 recognize as many as 7 to 9 different epitopes defined by their ability to block APN activity, bind to mouse transfectants expressing a mutant form of CD13, or block binding of other CD13-specific MAbs [24, 35]. The CD13-specific MAbs used in this study recognize at least three different epitopes according to this criterion.

Before any antibodies were used in the CMV neutralization assay (see below), they were dialyzed extensively against water and concentrated using a microdialyzer apparatus and concentrating solution (Pierce, Rockford, IL). The IgG concentration of the stock solutions was determined by ELISA (see below). Immunocytochemical stain for detection of the CMV mIE protein used a purified mouse IgG, E13 (ARGENE, Varilhes, France) or 9221 (NEN DuPont, Boston).

An immunoglobulin fraction from pooled serum from CMV-seropositive persons (intravenous immune globulin; IVIG) [34] and a CMV glycoprotein B (gB)—specific mouse MAb (7-5) [25] were used throughout this study as positive controls. IVIG has a high neutralizing titer toward CMV [36] and recognizes a number of proteins in lysates from CMV-infected cells by both immunoprecipitation [36] and immunoblot analysis [37] (including the products of CMV UL99 pp28 [37] and UL83 pp65 genes [data not shown]). The CMV neutralizing activity of serum from seropositive persons is primarily directed against gB [38, 39]. The gB-specific MAb 7-5 has high neutralizing activity [25]. IVIG and MAb 7-5 do not react with human CD13 in immunoblot analysis or bind to mouse cell transfectants expressing human CD13 (data not shown).

Determination of IgG concentration. IgG concentrations of the MAbs were determined quantitatively by a sandwich ELISA [40]. Briefly, 96-well EIA plates (Costar, Cambridge, MA) were coated overnight at room temperature with affinity purified goat anti-mouse or anti-human IgG (2 µg/mL; both from Sigma, St. Louis) in carbonate buffer. Plates were then incubated overnight at room temperature with a dilution series of unknown mouse MAbs or IVIG plus a standard mouse or human IgG (Sigma). The plates
were incubated with an alkaline phosphatase–conjugated goat anti-
mouse or anti-human IgG (both from Sigma) for 1 h at room
temperature. Finally, the substrate p-nitrophenyl phosphate (1 mg/ 
ml; Sigma) in ethanolamine, pH 9.7, was added and the free p-
nitrophenol was determined at 410 nm by microplate reader 
(MR6000; Dynatech Laboratories, Alexandria, VA). Between each 
incubation step, plates were washed four times with PBS con-
taining 0.05% Tween 20. Absorbance readings were converted 
IgG concentrations using Excel software (Microsoft, Seattle).

Inhibition of CMV infection by CD13-specific MAbs. The 
neutralization of CMV infection of MRC-5 or U373MG cells by 
CD13-specific MAbs was assayed as described [19]. In brief, dila-
tions of the test antibody and CMV were incubated in binding 
buffer (25 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 1 
mM MgCl2, 1 mg/mL bovine serum albumin [BSA], 1 mg/mL glucose, and 10 μg/mL phenol red) for 30–60 min at 4°C before 
being added to the cells. Monolayer cultures were incubated with 
virus alone or with virus and antibody for 2 h at 4° or 37°C. After 
incubation with virus, the cells were washed in complete medium 
in incubated at 37°C for 16–20 h, and assayed for CMV infection 
as described [19] by detection of expression of either the CMV 
mlE protein or β-gal if cells were infected with CMV RC256.

To test the ability of CD13-specific MAbs to neutralize unpass-
saged wild CMV, urine specimens from neonates with congenital 
CMV infection were used as a source of CMV. The specimens 
were stored in 25% buffered sucrose at −70°C until use. Samples 
were titrated and 100–200 infectious units were treated at 37°C 
for 1 h with 100 μg/mL CD13-specific MAB L138 or mouse IgG1, 
the isotype control, and cultured in 96-well plates on MRC-5 
monolayers for 18 h. The cells were assayed for infection by 
measuring the expression of mlE protein as described above.

Transfer of a CD13 immunoreactivity to CD13-negative cells. 
After NIH-3T3 cells were scraped from culture flasks into PBS 
and washed twice in PBS, 5 × 10² cells were incubated with 1.5 
ml of a CMV inoculum (5 × 10⁶ pfu/mL) for 30 min at room 
temperature. Infected or uninfected cells were then incubated with 
either a MAb directed toward CD13 (L138), CMV gB (7-5), the 
human fibroblast surface antigen (1B10), CD14 (McPd-9), CD9 
(FMC 8), or mouse IgG for 25 min at 4°C, followed by incubation 
with a phycoerythrin–conjugated F(ab')² fragment of a rabbit anti-
mouse immunoglobulin (Dakopatts, Glostrup, Denmark) for 20 
min at 4°C and finally resuspended in PBS and analyzed by flow 
cytometry as described below. Cells were washed twice with ice-
cold PBS between each incubation step.

Flow cytometry of cell surface CD13. The fluorescence signal 
from 5 × 10⁴ MRC-5, U373MG cells, hAPNMT-3T3 cells, or 10⁶ 
uninfected or infected NIH-3T3 cells was determined by flow 
cytometer (FACSort; Becton Dickinson, San Jose, CA) with an 
argon laser producing 15 mW of light at 488 nm as described 
[19]. For comparison of CD13 levels on the surface of MRC-
5 fibroblasts and U373MG and hAPNMT-3T3 cells, frequency 
distribution profiles of log₁₀ fluorescence of samples labeled with 
anti-CD13 (L138) or the isotype-matched control [MOPC21] were 
plotted, and a modal value of 1.0 was assigned to cells stained 
with the isotype-matched control. Dead cells labeled with propid-
ium iodide (0.5 μg/mL) were excluded from analysis.

For the NIH-3T3 cells, the frequency distribution profiles of 
log₁₀ fluorescence for uninfected and infected cells were compared 
for each antibody tested. A positive signal, defined by Kolmo-
gorov-Smirnov statistics [41], was an increase in the mean red 
fluorescence of NIH-3T3 cells greater than 10 channels when 
CMV-infected cells were compared with uninfected cells.

Immunogold labeling and electron microscopy of CMV virions. 
Aliquots (150 μL) of culture supernatants from AD169-infected 
HL734 fibroblasts were incubated 1 h at 23°C with 0.3 μg of 
CD10-specific MAb (L138), 12 μg of total mouse IgG, 5 μg of 
CD10-specific MAB (SS2/36), or 6.6 μg of CMV gB-specific MAB 
(7-5). A colloidal gold (10 nm)–conjugated goat anti-mouse IgG 
(Sigma) was added, and incubation was continued 1 h at 23°C. 
Virus particles were spun directly using a Microvett (Sarstedt, 
Langskrona, Sweden) onto formavar- and carbon-coated 400-mesh 
copper grids (Gilder Grids, Grantham, UK). Samples were exam-
ined by electron microscope (Philips CM 100) using 2% phospho-
tungstic acid as negative stain. The concentration of the CD13-
and CMV gB–specific MAbs was determined empirically based 
on the concentration that minimized formation of aggregates of 
virions, dense bodies, and gold particles. To quantitate the num-
ber of gold particles associated with CMV particles after labeling 
with the various MAbs, the specimen relocation system of the micro-
scope was used to randomly select areas for gold particle counting. 
Specimens were studied at ×25,000, and all virus particles were 
analyzed, including dense bodies in the preselected microscopic 
view. We counted 100 particles for each condition and determined 
the percentage of virus particles labeled with gold. Virus particles 
that were gold particle–positive were tallied according to the num-
er of particles associated with each individual virus particle.

Analysis of CMV virion proteins by SDS-PAGE and immunoblot. 
CMV virions and dense bodies were purified from media of in-
fected human fibroblasts using negative viscosity and positive-
density gradients as described by Talbot and Almeida [42]. Briefly, 
virus particles were collected from media of infected MRC-5 fi-
broblasts by centrifugation of cleared supernatants at 120,000 g 
(SW-28 rotor; Beckman, Brea, CA) for 45 min at 4°C through an 
8-mL 20% sucrose cushion. The pellet was resuspended in PBS, 
sonicated, layered on a 20%–70% sucrose gradient, and cen-
trifuged as above. Banded particles were collected, concentrated 
by centrifugation, layered onto a potassium tartrate–glycerol gradient 
formed as described by Talbot and Almeida [42], and centrifuged 
at 260,000 g (SW-41 rotor; Beckman) for 18 h at 4°C. The en-
veloped virus and dense body bands were collected, concentrated 
by centrifugation, resuspended in PBS, and stored at −70°C.

NIH-3T3 and hAPN-3T3 cell and MRC-5 fibroblast membranes 
were collected by scraping cell monolayers into TRIS-buffered 
saline (TBS; 20 mM TRIS-HCl, pH 7.2, 150 mM NaCl), pelleted 
by centrifugation (IEC Centra-7R; Damon/International Equip-
ment, Needham Heights, MA) at 800 g for 10 min, and homoge-
низed with 15 strokes in a Dounce homogenizer in TBS contain-
ing 4 μg/mL aprotinin, leupeptin, and soybean trypsin inhibitor 
(all from Sigma). The homogenate was centrifuged as above (800 
g, 10 min), and the pellet was rehomogenized and centrifuged. 
Membranes were purified from the combined supernatants by cen-
trifugation at 120,000 g in a Beckman SW-28 rotor for 45 min at 
4°C. The membrane pellets were resuspended in TBS and stored 
at −70°C. Protein concentrations were estimated by the bicinchoninic 
acid method [43]. BSA was the standard and reagents were used 
according to the manufacturer’s (Pierce) instructions.

Cellular membrane protein (10 μg) and protein from purified 
enveloped CMV virion and dense body preparations (30 μg) were
Table 2. CD13 antibody characterization.

| Antibody clone | Inhibition of CMV infection | Inhibition of APN activity | Binding to CD13 deletion mutant |
|----------------|-----------------------------|----------------------------|--------------------------------|
| L138           | +++                         | -                          | +                              |
| 8A3.1          | +++                         | -                          | +                              |
| 7B.1           | +                           | +                          | +                              |
| MY7            | +                           | +                          | +                              |
| SJ1D1          | +                           | -                          | +                              |
| RBS            | +                           | ++                         | -                              |
| 3D8            | -                           | +                          | +                              |
| U81            | -                           | +                          | -                              |
| 22A5           | -                           | ++                         | -                              |
| WM15           | -                           | +                          | -                              |
| WM47           | -                           | -                          | +                              |

* * - <25%; +, 25%-50%; ++, 50%-70%; ++++, >70%.

1 Inhibition of aminopeptidase N (APN) activity associated with surface of NIH-3T3 transfectants expressing human CD13: −, <40%; +, 40%-60%; ++, >60%.

2 Ability of antibody to bind to NIH-3T3 transfectants expressing mutated form of human CD13 lacking 39 amino acids from active site.

Results

Characterization of CMV neutralization by cell surface antigen-specific MABs. To characterize the inhibitory effect of CD13-specific MAbs on CMV infection, MRC-5 fibroblasts were incubated concurrently with MAb and virus inoculum (see Materials and Methods). We initially found that all CD13-specific MAbs inhibited CMV infection (data not shown); however, further characterization showed that the salt content of some antibody preparations was sufficient to inhibit CMV (data not shown). To avoid this, the MAbs were dialyzed into water and concentrated and assayed in parallel with a dialyzed salt control. We tested the ability of 11 different CD13-specific MAbs to protect MRC-5 fibroblasts from CMV infection (table 2). Four MAbs strongly inhibited CMV infection, 2 had weak inhibitory activity, and 5 had none.

Figure 1 shows the three levels of inhibitory activity of the CD13-specific MAbs and of antibodies directed toward two other cell surface antigens (CD9 and the epidermal growth factor receptor), IVIG used as a positive control, and the isotype controls. If the cells were infected in the presence of the CD13-specific MAbs, CMV infection was inhibited in varying degrees: 8A3.1 inhibited CMV to 23.6% ± 4.5% (mean ± SE) of the level of the control, SJ1D1 inhibited CMV to 57.5% ± 6%, and 3D8 had no inhibitory activity (100.8% ± 9.7%; figure 1). The positive control, IVIG, inhibited infection to 36.4% ± 2%; the isotype controls, IgG1 and IgG2a, and the antibodies directed toward CD9 and the epidermal growth factor receptor had no effect on CMV infection (figure 1). These results indicate that the antiviral activity of CD13-specific MAbs is not merely due to interactions with an Fc receptor, to nonspecific binding, or to binding to any antigen on the cell surface.

Antibodies capable of inhibiting CMV infection can be placed in three groups according to their ability to bind to NIH-3T3 transfectants that express a mutated form of human CD13 lacking 39 aa from the active site (hAPNMUT-3T3) [21] and...
inhibit APN activity of NIH-3T3 transfectants that express native human CD13 (hAPN-3T3) [20] (table 2). The three antibody groups are as follows: those that bind to hAPNMUT-3T3 cells and inhibit APN activity (e.g., MY7), those that bind to hAPNMUT-3T3 cells but do not inhibit APN activity (e.g., L138, 8A3.1, 7B.1, and SJ1D1), and those that do not bind to the deletion mutant but do inhibit APN activity (e.g., mouse MAb RBS).

When the MRC-5 fibroblasts were incubated with antibody and excess antibody was washed away before infection with untreated inoculum, none of the antibodies tested inhibited CMV infection (data not shown). These results suggest that CD13-specific MAbs inhibit CMV infection by an interaction with the virus rather than with the host cell.

**CD13-specific MAbs protect CD13-negative cells from CMV infection.** To test whether CD13-specific MAbs interact with CMV per se, we studied the effect of these MAbs on infection of CD13-negative cells. U373MG and MRC-5 cells were infected with CMV RC256 (figure 2A) in the presence of CD13-specific MAb 8A3.1, the isotype-matched negative control (IgG1), or IVIG (positive control). Infection of MRC-5 and U373MG cells by CMV was inhibited both by the CD13-specific MAb and by IVIG. The isotype-matched control for the CD13-specific MAb showed no protective effect. Flow cytometry of these cells (figure 2B, C), using either a CD13-specific MAb or the isotype-matched control, confirmed that the U373MG cells (figure 2B) had no detectable binding of the CD13-specific MAb but that the MRC-5 cells (figure 2C) had significant binding of the CD13-specific MAb. We have tested whether CD13-specific MAbs can protect CD13-negative mouse cells [19] from CMV infection. Like the U373MG cells, the NIH-3T3 cells also were protected by a CD13-specific MAb and IVIG but not by the isotype-matched control (data not shown). Since the CD13-specific MAb does not bind to the U373MG or NIH-3T3 cells, the neutralization of CMV by this MAb suggests that it reacts directly with an epitope on the CMV virion.

Transfer of a virus-associated CD13-like molecule to CD13-negative cells. To confirm that a CD13-like molecule is associated with CMV virions, we indirectly measured the presence of cell-surface molecules associated with the CMV envelope by comparing the surface immunoreactivity of human CD13-negative murine cells before and after CMV binding. NIH-3T3 cells were analyzed by flow cytometry for the presence of human cell surface antigens, including CD13, and CMV gB before or after incubation with CMV. Flow cytometry of the uninfected NIH-3T3 cells showed no binding of the human CD13-specific MAbs L138 (figure 3C) or WM47 (data not shown) or of the anti-CMV gB-specific MAb 7-5 (figure 3E). The NIH-3T3 cells showed a marked increase in the binding of anti-CMV gB MAb, detected as an increase in mean fluorescence, after incubation with CMV (figure 3E, F [shaded areas]), indicating that CMV gB was associated with the NIH-3T3 cells, presumably by binding CMV virions. The binding of CMV to the NIH-3T3 cells resulted in a significant increase in binding of both CD13-specific MAbs L138 and WM47 (figure 3C, D [shaded areas], and data not shown). The negative control antibodies (1 directed toward CD14 [McPP-9] and another to mouse IgG) did not bind to the NIH-3T3 cells before or after CMV binding (figure 3A, B [open tracing], and data not shown). The binding to the NIH-3T3 cells by 2 other antibodies specific for the cell surface proteins CD9 (FMC 8) and a human fibroblast surface antigen (1B10), both present on MRC-5 fibroblasts, was not affected by incubation of the cells with CMV (data not shown). The binding of CMV to a cell results in transfer of human CD13 immunoreactivity, suggesting that a CD13-like molecule is associated with CMV particles.

**Immunogold labeling of CMV.** To test directly if CD13-specific MAbs interact with CMV, MAbs were assayed for their

---

**Figure 2.** Inhibition of CMV infection of CD13-negative cells with antibodies to human CD13. A, Level of CMV infection of monolayer cultures of U373MG cells or MRC-5 fibroblasts, if infected, in presence of CD13-specific antibody 8A3.1; isotype-matched control, IgG1; or immunoglobulin fraction from pooled CMV-seropositive persons (IVig), all at 100 μg/mL. Infection level is expressed as % of dialyzed buffer control (mean ± SE). B, C, Flow cytometry of surface expression of CD13 in MRC-5 fibroblasts and U373MG cells, respectively. Fluorescence levels are shown after binding of CD13-specific monoclonal antibody (L138, thick line) or isotype-matched control antibody (IgG1, thin line).
Figure 3. Flow cytometry of CD13 and CMV glycoprotein B (gB) on NIH-3T3 cells after infection with CMV. NIH-3T3 cells were stained with CD13-specific monoclonal antibody (MAb) L138 (C, D, shaded area), CMV gB-specific MAb 7-5 (E, F, shaded area), or mouse IgG (A–F, open area) before (A, C, E) or after (B, D, F) CMV infection.

Figure 4. Immunogold labeling of CMV virions with CD13-specific antibodies. Aliquots of AD169 inoculum were incubated with CMV glycoprotein B–specific antibody (A), mouse IgG (B), CD10-specific antibody (C), or CD13-specific antibody (D) followed by gold-conjugated secondary antibody. Samples were analyzed by transmission electron microscopy. Magnification: ×230,000 (A, D), ×190,000 (B, C).

ability to bind to virions by immunogold labeling of virions and analyzed by electron microscopy (see Materials and Methods). Significantly more gold particles bound to virion envelopes (figure 4) and dense bodies (data not shown) when the primary MAb was either CMV gB-specific (figure 4A) or CD13-specific (figure 4D) than when the primary antibody was CD10-specific or mouse IgG (figure 4C, B, respectively). The number of gold particles associated with CMV particles was quantitated as described in Materials and Methods. When we compared the number of gold particles associated with 100 CMV particles labeled by each of the primary antibodies (table 3), we found that virus particles labeled with the negative mouse IgG control usually had 0–2 gold particles on their surfaces. Therefore, we considered that 0–2 gold particles indicated a nonspecific interaction of the primary antibody with virus particles.

Gold particles were associated with 67% of virus particles labeled with antibody specific to CMV gB compared with 40% of virus particles incubated with a CD13-specific MAb (table 3). Only 1% of the particles labeled with mouse IgG or the CD10-specific MAb had >2 gold particles associated with them. As shown in table 3, virions incubated with CD13-specific MAbs had significantly fewer associated gold particles than virions incubated with the gB-specific MAb, (3.07 ± 2.42 vs. 4.47 ± 2.88 [mean ± SD]; P = .0013). The CD13-specific MAb-labeled CMV particles had significantly more gold particles bound than did virus particles labeled with a CD10-specific
Table 3. Immunogold labeling of CMV particles with CD13-specific monoclonal antibodies.

| Antibody   | No. of antibody linked gold particles bound to CMV particles* | % CMV particles labeled with gold particles† | No. of gold particles associated with CMV particles‡ |
|------------|-------------------------------------------------------------|---------------------------------------------|---------------------------------------------------|
| mlgG       | 99 1 0 0                                                   | 1.42 ± 0.55                                  |                                                   |
| CD10       | 99 1 0 0                                                   | 1.35 ± 0.52                                  |                                                   |
| CD13       | 60 34 3 3                                                 | 3.07 ± 2.42                                  |                                                   |
| Glycoprotein B | 33 38 22 7                                           | 4.47 ± 2.88                                  |                                                   |

* CMV particles grouped by no. of associated gold particles.
† % CMV particles labeled with >2 gold particles.
‡ No. of gold particles associated with CMV particles (mean ± SD).

MAb (1.35 ± 0.52; P = .0001) or a mouse IgG (1.42 ± 0.55; P = .0001). The CD10-specific MAb used for these experiments is the same isotype as the CD13-specific MAb, indicating that the interaction of the CD13-specific MAb is not merely via the Fe receptor. These experiments show that CD13-specific MAbs bind directly to CMV virions and dense bodies.

Immunoblot analysis of CD13-like molecules associated with CMV virions. In an attempt to determine which CMV molecules are immunoreactive with CD13-specific MAbs, we analyzed immunoblots of purified virion proteins. CMV virions and dense bodies were purified using negative viscosity: Positive density gradients [42] and virus particle proteins were fractionated by SDS-PAGE and assayd for immunoreactivity to a CD13-specific MAb (3D8; figure 5A) and the isotype control (UPC10; figure 5B). The CD13-specific MAb was immunoreactive with as many as seven bands in the fractionated proteins of CMV dense bodies (figure 5A, lane 5). The major band (apparent molecular mass, 150 kDa) was also visible in fractionated proteins from CMV-enveloped virions along with a cluster of three very faint 95- to 115-kDa bands (figure 5A, lane 4). The 150-kDa immunoreactive band in CMV virions and dense bodies has a similar apparent molecular mass by SDS-PAGE to that of native human CD13 expressed in hAPN3T3 cells (figure 5A, lane 1 arrow) and faintly evident in membranes from MRC-5 fibroblasts (figure 5A, lane 3). The other major immunoreactive bands at 137- and 86-kDa in the cell membrane fractions recognized by the CD13-specific MAb (figure 5A, lanes 1–3) were also recognized by the isotype control antibody (figure 5B, lanes 1–3), indicating a nonspecific interaction. If the CD13-specific MAb is preabsorbed with a soluble form of CD13 purified from hyb7.2 cell media [22] as described in Materials and Methods, only the 137- and 86-kDa bands are visible on the immunoblot (data not shown). These immunoblot data indicate that CD13-specific MAbs recognize a number of proteins, including a 150-kDa protein, that are associated with purified virions and dense bodies.

Inhibition of natural unpassaged CMV with CD13-specific MAbs. Because laboratory CMV strains are generally propagated in CD13-positive human fibroblasts, it is possible that the introduction of CD13 to the virion is a tissue culture artifact. To test whether a CD13-like molecule is associated with CMV in nature, we used previously frozen and virus-titered urine samples of neonates with congenital CMV infection. A total of 100–200 infectious units of such unpassaged virus were incubated with a mixture of 2 CD13-specific MAbs (8A3.1 and 7B.1) and cultured with MRC-5 cells. Fibroblast infection by natural CMV was inhibited 89% by CD13-specific MAbs (table 4) and not at all by the isotype control. The clinical sample and laboratory strain AD169 (diluted and tested in urine from a seronegative female volunteer) were similarly inhibited (89% and 98%, respectively). Thus, CD13-specific MAbs inhibit natural unpassaged CMV, indicating that a CD13-like molecule is associated with natural and clinically relevant CMV strains and not merely a laboratory artifact derived by culturing virus in CD13-positive cells.

Discussion

In the current study, we extended our initial observations that CD13-specific MAbs inhibit CMV infection by showing...
that the inhibition is caused by an interaction between the MAbs and virion-associated epitopes. The interaction between MAbs and virus appears to be via an antigenic molecule that is physically attached to CMV as shown by immunogold labeling with CD13-specific MAb and by the transfer of CD13 immunoreactivity upon binding of CMV to CD13-negative cells.

A number of antigenic molecules are associated with purified virions and dense bodies, including one with similar molecular mass (by immunoblot analysis) to native human CD13. Natural unpassaged CMV is similarly neutralized by CD13-specific MAbs, showing that this is not merely a laboratory artifact acquired by passage in human fibroblasts. As shown previously [19], CD13-specific MAbs do not inhibit infection by a closely related member of the herpesvirus family, herpes simplex virus type 2. Thus, neutralization of CMV by anti-CD13 is specific and suggests that a CD13-like molecule associated with CMV plays an important role in CMV infection [45].

Although the role of CD13 in CMV infection is incompletely understood, the results of this study and our previous findings [19] suggest that interactions between the host cell and the virus involve CD13 in a way that enhances infection. The data from the present study provide some information about these interactions. Our prior study showed that expression of human CD13 on the surface of a mouse cell increases the susceptibility of the cells to human CMV infection. This suggested that cellular CD13 (cCD13) interacts with a virion protein. The present study shows that CD13-specific MAbs can neutralize CMV infection by interacting with CD13 or a CD13-like molecule associated with virions, but that the MAbs do not interfere with infection when bound to the cell surface. The effect of these MAbs on CMV can be explained by at least three hypotheses: first, that antibody binds to the cell and virus via the same epitope that exists in different proteins and that the CD13-like molecule associated with CMV is not CD13; second, that antibody binds to CD13 on the cell and on the virus, but the interactions of these proteins necessary for enhancing infection involve different ligands for the cCD13 compared with viral CD13; and third, that the antibody binds to CD13 on the cell and virus, and the proteins interact with the same or a homologous protein that exists on the virus and the cell.

Our data disprove the third hypothesis, since antibody bound to the cell surface does not inhibit CMV infection. The data do not exclude the other two hypotheses. Not all CD13-specific MAbs neutralize infection; however, at least 2 MAbs that lack neutralizing activity, 3D8 and WM47, bind to CMV virions as shown by immunoblot and FACS analyses after the transfer of immunoreactivity by binding of CMV virions to CD13-negative cells (figure 5; data not shown). In fact, these data indicate that at least 8 of 11 different MAbs used in this study interact with CMV virions. The ability of these MAbs to inhibit CMV infection and APN activity or to bind to the mutated form of CD13 (table 2) suggests that these 8 antibodies recognize as many as 5 different CD13 epitopes and supports the second hypothesis that the immunoreactive protein associated with CMV particles is actually cCD13.

We have compared the cDNA-deduced protein sequence for human CD13 [20] to the deduced protein sequences of the known and suggested open-reading frames encoded by the CMV AD169 genome [4]. There were no long stretches of significant sequence homology to human CD13 within the CMV genome, indicating there is no CMV homologue to human CD13. However, this analysis identified a number of short peptide sequences (5–11 aa long) from the deduced sequence of putative CMV glycoproteins. These short homology sequences could represent linear epitopes or regions of discontinuous epitopes to which these antibodies bind [45, 46]. For example, Fujinami et al. [9] showed that a peptide from a protein encoded by the CMV IE-2 region, containing 5 aa, is identical to an HLA-DR{3} chain peptide and induces antibodies that cross-react with HLA-DR [9]. Thus, it is possible that a peptide from some CMV surface protein is similar in sequence to a natural CD13 epitope.

Our current working hypothesis is that cCD13 and a viral CD13-like molecule interact with a viral or cellular protein, respectively, and that both interactions enhance viral infection. How then does this hypothesis explain that CD13-negative cells, such as U373MG (see figure 2), can be infected with CMV [47, 48]? Although we do not know the answer, we believe there are at least two possible explanations: First, cCD13 is important for CMV infection but not the only mechanism of CMV uptake and it is not essential; and second, in CD13-negative cells, another mechanism of uptake predominates, but in CD13-positive cells, the CD13-mediated uptake is a supplementary method that enhances CMV uptake. Other enveloped viruses have multiple entry pathways [49, 50]. For example, human immunodeficiency virus can infect CD4-negative cells via pathways involving sphingolipid galactosyl ceramide or the Fe receptor (reviewed in [49]). Further study is needed to determine if CD13 or some homologue is necessary for CMV infection. A number of cell surface molecules play a role in the initial events of CMV infection of fibroblasts.

### Table 4. Inhibition of natural, unpassaged CMV with CD13 antibody.

| Specimen | Antibody      | Level of infection % |
|----------|---------------|-----------------------|
| 829N     | anti-CD13     | 12 (7, 16)            |
|          | IVIG          | 69 (74, 63)           |
|          | IgG1          | 121 (130, 112)        |
| AD169    | anti-CD13     | 3 (2, 3)              |
|          | IVIG          | 13 (14, 12)           |
|          | IgG1          | 100 (98, 102)         |

**NOTE.** CD13-specific monoclonal antibody, isotype negative control, or IVIG (intravenous immune globulin) as positive control were tested for ability to neutralize CMV in urine specimen from neonate. Level of infection is shown as % of level in control infected in presence of equivalent volume of dialysed buffered saline. Values listed are mean of 2 separate determinations; values for individual determinations are in parentheses.

Anti-CD13 CMV Neutralization 1069
(summarized in [51]). How CD13 interacts with these proteins remains to be determined.

This study shows that CMV from natural infection has a CD13-like molecule associated with infectious particles. This suggests that a better understanding of the physical characteristics of the CD13-like molecule(s) associated with CMV particles, including the sequences recognized by CD13-specific MAbs that neutralize CMV, might increase our understanding of CMV infection, disease, and pathogenesis. In this regard, it is important to consider that a CD13-like molecule associated with CMV might play an important role in the immunologic response of the host to CMV. Immune responses initiated towards viral antigens sharing homology with host cell proteins can lead to autoimmune responses [52, 53]. Our recent data show that some bone marrow transplant patients with CMV disease or infection have cytotoxic antibodies with specificity toward CD13 [17]. The production of such autoantibodies could contribute to tissue damage during graft-versus-host reactions in the bone marrow transplant patient [18] or to graft rejection in the solid organ transplant recipient. Whether the CD13-like molecule associated with CMV virions is cellular CD13 or an immunologically related molecule, this association should be considered in the elucidation of interactions of CMV pathogenesis.

Acknowledgments

We thank J. Bolen and C. Ahn, City of Hope National Medical Center, for flow cytometry of the MRC-5 and U373MG cells and statistical analysis of the immunoglobulin-labeled CMV particles, respectively; W. Britt, University of Alabama, Birmingham, for 7-5, a mouse MAb to CMV gB; K. Holmes, Uniformed Services University of the Health Sciences (Bethesda, MD) for RBS, a mouse MAB to CD13; T. Piela-Smith, VA Medical Center (Newington, CT) for mouse MAbs to CD13, 8A3.1, and 7B.1; I. Raba­

References

1. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988; 108:585–94.
2. Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS. Infection disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977; 24:458–64.
3. Zaia J. Viral infections associated with bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4:603–23.
4. Chee MS, Bankier AT, Beck S, et al. Analysis of the protein-coding content of the human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990; 154:125–69.
5. Shaw SB, Rasmussen RD, McDonough SH, Staprans SI, Vacquier JP, Spector DH. Cell-related sequences in the DNA genome of human cytomegalovirus strain AD169. J Virol 1985; 55:843–8.
6. Rüger R, Bornkamm GW, Fleckenstein B. Human cytomegalovirus DNA sequences with homologies to the cellular genome. J Gen Virol 1984; 65:1351–64.
7. Staprans SI, Spector DH. 2.2-kilobase class of early transcripts encoded by cell-related sequences in human cytomegalovirus strain AD169. J Virol 1986; 57:591–602.
8. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to HLA class I antigens. Nature 1988; 331:269–72.
9. Fujiyama RS, Nelson JA, Walker L, Oldstone MBA. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR β chain: a means for graft rejection and immunosuppression. J Virol 1988; 62:100–5.
10. Michelson S, Tardy-Panit M, Coliman R, Landini MP. A human cytomegalovirus-neutralizing monoclonal antibody recognizes a normal cell protein. J Gen Virol 1989; 70:673–84.
11. Grundy JE, McKeating JA, Griffiths PD. Cytomegalovirus strain AD169 binds β2-microglobulin in vitro after release from cells. J Gen Virol 1987; 68:774–84.
12. Wright JF, Kurosky A, Prydzial ELG, Wasi S. Host cellular annexin II is associated with cytomegalovirus particles isolated from cultured human fibroblasts. J Virol 1989; 63:4784–91.
13. Landini MP, Ripatti A. A DNA-nicking activity associated with the nucleocapsid of human cytomegalovirus. Arch Virol 1982; 73:351–6.
14. Benson JD, Huang ES. Human cytomegalovirus induces expression of cellular topoisomerase II. J Virol 1990; 64:9–15.
15. Wiley D. HCMV gene in cytomegalovirus. Nature 1988; 331:209–10.
16. Fujinami RS, Oldstone MBA, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: cross-reaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci USA 1983; 80:2346–50.
17. Söderberg C, Sumitran-Karuppan S, Ljungman P, Möller E. CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation 1996; 61 (in press).
18. Söderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Möller E. Cytomegalovirus induced CD13-specific autoimmunity: a possible cause of chronic graft versus host disease. Transplantation (in press).
19. Söderberg C, Giugni TD, Zaia JA, Larsson S, Wahlberg JM, Möller E. CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol 1993; 67:6576–85.
20. Look AT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989; 83:1299–307.
21. Ashmun RA, Shapiro LH, Look AT. Deletion of the zinc-binding motif of CD13/aminopeptidase N molecules results in loss of epitopes that mediate binding of inhibitory antibodies. Blood 1992; 79:3344–9.
22. Vogel LK, Norén O, Sjöström H. The apical sorting signal on human aminopeptidase N is not located in the stalk but in the catalytic head group. FEBS Lett 1992; 308:14–7.
23. Späte RR, Mocarski ES. Insertion and deletion mutagenesis of the human cytomegalovirus genome. Proc Natl Acad Sci USA 1987; 84:7213–7.
24. Look AT, Ashmun RA, Shapiro LH, et al. Report on the CD13 (aminopep­titase N) cluster workshop. In: Knapp W, Dorken B, Gilks WR, et al., eds. Leucocyte typing. IV. White cell differentiation antigens. Oxford, UK: Oxford University Press, 1987; 784–7.
25. Brit W. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 1984; 135:369–78.
26. Look AT, Peiper SC, Ashmun RA. Binding of independently derived monoclonal antibodies to unique human myeloid differentiation anti­gens. In: McMichael AJ, Beverley PCL, Gilks W, et al., eds. Leucocyte typing. III. White cell differentiation antigens. Oxford, UK: Oxford University Press, 1987: 626–9.
27. Favalaro EJ, BradstockKF, Kabral A, Grimsley P, Zowy H, Zola H. Further characterization of human myeloid antigens (gp160, 95; gp150;
27. Piela-Smith T, Korn JH. Aminopeptidase N: a constitutive cell-surface protein on human dermal fibroblasts. Cell Immunol 1995;162:42–8.
28. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 1992;357:420–2.
29. Gadd S. Cluster report: CD13. In: Knapp W, Dorken B, Gilks WR, et al., eds. Leucocyte typing. IV. White cell differentiation antigens. Oxford, UK: Oxford University Press, 1989:782–4.
30. Singer KH, Scearce RM, Tuck DT, Whichard LP, Denning SM, Haynes BF. Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages. J Invest Dermatol 1989;92:166–70.
31. Dimitriu-Bona A, Burmester GR, Waters SL, Winchester RL. Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol 1983;130:145–52.
32. McKenzie IFC, Zola H. Monoclonal antibodies to B cells. Immunol Today 1983;4:10–5.
33. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamine decarboxylase and Coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994;94:2125–9.